Nutrition Journal

Table 3 Final subject disposition by group and visit

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

		Group
		UP446250 mgs/day	UP446500 mgs/day	Celecoxib 200 mgs/day	Placebo
Visit	Baseline	15	15	15	15
	30 Days	15	15	13	15
	60 Days	14	13	13	13
	90 Days	14	13	12	13

Back to article page

ISSN: 1475-2891

Contact us

General enquiries: journalsubmissions@springernature.com